<DOC>
	<DOCNO>NCT02104011</DOCNO>
	<brief_summary>Treatment angiomyolipomas base invasive technique surgery embolization . Development anti-angiogenic therapy major grow field research hypervascularized tumor . Angiomyolipomas show regress prolong treatment mTOR inhibitor ( Sirolimus ) , large proportion secondary effect . We show recently beta-blockers able induce regression infantile hemagiomas . Consequently , look find , histologically , case angiomyolipomas presence beta2 receptor . The aim study estimate beta-blockers could induce regression stabilization renal angiomyolipomas tuberous sclerosis pilot study .</brief_summary>
	<brief_title>Treatment Renal Angiomyolipomas Tuberous Sclerosis Beta-blockers</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Tuberous Sclerosis</mesh_term>
	<mesh_term>Angiomyolipoma</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Tuberous sclerosis patient one several angiomyolipomas size least 4 cm . Patients CT MR scan show one several intralesional aneurism require preventive embolization . Patients retroperitoneal hemorragic complication require preventive embolization . Patients biopsy show adenocarcinoma , hypertension non control , renal failure severe liver . Diabetic subject insufficiently control . Betablockers contraindication . Psychosis , severe mental disorder . Patient already treat betablockers mTOR inhibitor . Pregnant nursing woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Angiomyolipomas tuberous sclerosis</keyword>
	<keyword>Beta-blockers</keyword>
	<keyword>Anti-angiogenic therapy</keyword>
</DOC>